Certara, Inc.
Certara, Inc. (Nasdaq: CERT) provides biosimulation software, scientific and regulatory technology, and consulting services to support model-informed drug development for biopharmaceutical and biotech companies. Its tools and experts help customers analyze drug behavior, design clinical trials, standardize and… From the company’s description.
Over the twelve months to Sep 30, 2026, Certara, Inc. reported revenue of $385.91M, down 7.1% from a year earlier, and a net loss of $27.38M. Its operating margin was −0.9%, and operations generated $81.23M in cash. In fiscal 2025, it reported revenue of $418.84M, up 8.7% from fiscal 2024, and a net loss of $1.59M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Certara, Inc. does
In the company’s own words
Certara, Inc. (Nasdaq: CERT) provides biosimulation software, scientific and regulatory technology, and consulting services to support model-informed drug development for biopharmaceutical and biotech companies. Its tools and experts help customers analyze drug behavior, design clinical trials, standardize and validate research data, and prepare regulatory submissions; customers also include contract research organizations, academic and government institutions, regulators, and organizations in animal health, crop science, bioscience, and medical devices. Certara’s portfolio includes Simcyp and Phoenix biosimulation platforms, Pinnacle 21 clinical data tools, CoAuthor and GlobalSubmit regulatory software, and Chemaxon scientific informatics products. The company combines licensed software with technology-enabled services in areas such as pharmacometrics, clinical pharmacology, quantitative systems pharmacology, and regulatory strategy and operations. It has acquired businesses including Simcyp, Pinnacle 21, and Chemaxon to expand its capabilities from drug discovery through commercialization. In 2025, Certara served more than 2,600 life sciences companies and academic institutions, and employed 1,576 professionals in 28 countries. Its website is www.certara.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Prepackaged Software
- Headquarters
- RADNOR, PA
- Fiscal year end
- December
- CIK
- 1827090
- SIC
- 7372
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Certara, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Certara, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Certara, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Certara, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Certara, Inc.'s last four quarterly filings that the numbers alone won't show?”